Shanghai Dunwill Medical Technology Development Co., Ltd. (hereinafter referred to as "Dunwill Medical") recently completed a Series A financing of several hundred million yuan, jointly led by Luxin Venture Capital and Tongchuangwei Fund, with Qianhai Foundation, Qudao Asset, and Jintou Zhiyuan participating in the investment. After obtaining this round of financing, the company will further increase investment in research and development of original biomarker, strengthen talent team building, improve enterprise production capacity, and continue to promote the transformation and commercialization of key research and development projects. Life Capital serves as the exclusive financial advisor for this financing.

Driven by clinical needs, based on our insight of system biology and multi-omics technology, we work with clinical experts on the development mechanism of complex diseases from the “spatial and temporal dimension” and develop original clinical IVD products with own independent intellectual property rights.

Dunwill Medical was founded in 2006 and is headquartered in Caohejing Technology Oasis, Songjiang Science and Technology City, Lingang, Shanghai. It is a high-tech enterprise that integrates research and development, production, medical testing, and sales. Under the innovative closed-loop cooperation model of "medical-research-production", after more than ten years of efforts, Jusbio Sciences and Epione Medlab, two biomedical high-tech enterprises of Dunwill, is a one-stop solution provider of multi-omics R&D platforms, covering genomics, cell phenomics, proteomics, bioinformatics and AI etc. have an SPF level animal experimental center certified by the Shanghai Municipal Science and Technology Commission, and have successfully established PDX and CDX animal model libraries. Our products covering treatment stages such as early disease diagnosis, efficacy monitoring, recurrence warning, and more drug accompanied diagnosis.

Dunwill Medical, driven by clinical needs as its core, maintains a long-term stable cooperative relationship with the top 100 hospitals in the country, and has initially established a complete ecosystem from innovative development to commercial application.

Ms. Sofia Wen, founder of Dunwill Medical stated:

“Thanks very much for investment support from top professional institutions such as Luxin Venture Capital and Tongchuang Weiye! True innovation and original research start from scratch. Faced with numerous clinical problems and complex pathogenesis, we need to be diligent in thinking and persistent in trial and error. There is no possibility of overtaking in the path of medical innovation or pushing others around the bush! Respecting science and respecting life are the basic qualities of our biopharmaceutical professionals. We are very fortunate to have all the opportunities during our development, we encountered partners who provided us with growth opportunities. As the founder and CEO, we will respect the work of various functional departments of the company and focus on our own learning. We will maintain a friendly, fair and equal cooperation with investors, actively integrate resources from all parties, and face competition and challenges in the company's development process calmly. Under the original "medical research production" ecosystem, we will continuously develop more original research products to serve Chinese patients and doctors!”

The miRNA7^TM test kit has obtained price barcodes from 23 provinces and cities, and has been included in the Shanghai medical insurance reimbursement catalog

Dunwill Medical and Zhongshan Hospital affiliated to Fudan University jointly developed multiple products, including early diagnosis of liver cancer using microRNA, early warning of liver cancer metastasis and recurrence using circulating tumor cells (CTC), and targeted therapy guided by a tissue transplantation model (PDX) from liver cancer patients. They have won the second prize of National Science and Technology Progress Award, the first prize of Shanghai Science and Technology Progress Award, and the first prize of Huaxia Medical Science and Technology Award.

Investors say:

“Dunwill Medical, in collaboration with Zhongshan Hospital affiliated to Fudan University, has developed and transformed seven miRNA7TM test kits. As the first miRNA liver cancer test kit in the world, it has obtained the National Class III Medical Device Registration Certificate (National Medical Device Registration No. 20173403299) and has been included in the 2019 and 2022 versions of the National Health Commission's primary liver cancer diagnosis and treatment guidelines (Evidence Level 1, Recommendation A). Currently, it has been promoted and applied in clinical practice in tertiary hospitals nationwide. "The liver cancer diagnostic model established using the expression levels of seven plasma miRNAs can not only accurately diagnose very early liver cancer, but also has a sensitivity improvement of about 30% compared to the traditional liver cancer marker AFP.”

Mr. Du Lin, partner of Huaxin Capital under Luxin Venture Capital, stated:

“Medical and health care is the key direction of Luxin Venture Capital's layout. We are pleased to accompany a group of innovative enterprises such as Dunwill Medical to lead the rapid development of the medical industry and do things of great significance to life and health. Dunwill Medical has an experienced multi-disciplinary research and development team and a multi omics analysis platform. From the study of complex disease mechanisms, it excavates original biomarkers and converts them into clinical diagnostic products, solving unmet clinical needs. It is a rare enterprise in the industry that has all the capabilities from research, development to commercialization. We acknowledge the company's team's passion for the healthcare industry and have witnessed the company's innovative spirit and ability to solve clinical problems. We are honored to work together with the company to promote clinical innovation and product application.”

Mr. Liu Yimin, Managing Director of Tongchuang Weiye, stated:

“Thanks to Ms. Wen's team for giving Tongchuang the opportunity to participate in this round of investment of Dunwill Medical. We think highly of Dunwill’s vision to have an early layout in the tumor early screening market, which is worth billions of yuan. Dunwill has achieved remarkable results, especially in collaborating with Zhongshan Hospital to develop and the first miRNA liver cancer test kit in the world, which won the second prize of National Science and Technology Progress Award; Dunwill Medical has the ability and collaborative resources to continuously develop more original research products within the original "medical-research-production" ecosystem. We believe that through the efforts of Mr. Wen's team, Dunwill Medical will grow into a globally leading IVD listed company specialized in the research, development and commercialization of original biomarkers.

As a domestic first tier investment institution deeply rooted in the medical field, Tongchuang Weiye has numerous investment layouts in fields such as biopharmaceuticals, medical devices, medical services, and IVD. Looking forward to more cooperation with Dunwill Medical in industrial synergy.”

About Lucion

Lucion Group Co., Ltd. (referred to as "Luxin Venture Capital", SH.600783) is an A-share listed company mainly engaged in venture capital. It is a professional venture capital institution with significant influence in China controlled by Shandong Luxin Investment Holding Group Co., Ltd. The life and health industry, as a key layout and investment sector of Luxin Venture Capital, focuses on and invests in countries and regions such as China, the United States, the European Union, and Israel. The well-known medical and health companies that the company has invested in include: 3D Medicines, Rongchang Biotechnology, ABclonal, Applied Protein Technology, Sibionics, Bayzed Healthcare, Monad, Bozwin, Realbio Technology, WeMed Medical, Targene Biotech, etc.

About Cowin Capital

Founded in 2000, Cowin Capital is one of the first local PE/VC frontline investment institutions in China. Over the past 22 years, it has managed assets of over 30 billion RMB and invested in over 500 companies, successfully promoting IPOs or mergers and acquisitions of over 100 companies; More than 100 companies have been invested in the medical and health field, and more than 20 have gone public through IPOs or mergers and acquisitions; Having rich investment experience in the medical and health industry, we have been selected multiple times as one of the top 20 investment institutions in China and the top 10 investment institutions in the medical and health field; Successful investment cases in the medical and health field such as: Daan Gene, Betta Pharmaceutical, Innovent Biotechnology, BGI, Chipscreen, Lifotronic, Venus Medtech, Tianzhixing, ACRO Biosystems, United Imaging, Aim, China Resources Biotechnology, etc.

About Life Venture Partners

Life Venture Partners, with the mission of becoming a leader in the health industry, is a leading financial service institution in China that focuses on the field of big health. Its subsidiaries cover investment banking and venture capital businesses. The team members come from well-known investment banks, academic institutions, and medical enterprises, with decades of experience in the fields of healthcare and investment and financing.

In the past few years, the team has completed financing and mergers and acquisitions in dozens of medical industries, with a cumulative amount of tens of billions of yuan, covering various sub sectors such as new drug research and development, medical devices, diagnosis, consumer medicine, medical services, smart healthcare, and health insurance. In the selection of Chinese financial advisory firms organized by financial big data institution Qiming Technology, Life Capital was selected as the top 3 financial advisory firms in the field of healthcare in China. In the Top 100 Future Medical Activities of the Arterial Network, Life Capital was named the "Annual Medical Financial Advisory Institution".